Document Type
Article
Publication Date
9-13-2018
ISSN
0028-4793
Publisher
Massachusetts Medical Society
Language
en-US
Abstract
Pharmaceuticals are consuming increasingly large portions of U.S. state budgets, and high prices are preventing patients from getting, and adhering to, essential medicines. In mid-May 2018, President Donald Trump announced a heavily hyped but relatively modest federal plan to bring down drug prices. Meanwhile, several states are moving forward with their own solutions, and Maryland’s approach is particularly ambitious. In 2017, responding to notorious cases such as the 5000% increase in the cost of Daraprim (pyrimethamine) and the 10-fold increase in the cost of EpiPens (epinephrine auto-injectors), Maryland enacted a statute that prohibits manufacturers from “price gouging” on any “essential off-patent or generic drug.”
Recommended Citation
Christopher Robertson,
Will Courts Allow States to Regulate Drug Prices?
,
in
379
The New England Journal of Medicine
1000
(2018).
Available at:
https://scholarship.law.bu.edu/faculty_scholarship/963
Comments
From The New England Journal of Medicine, Christopher T. Robertson, Will Courts Allow States to Regulate Drug Prices?, Volume 379, Page 1000 Copyright © (2018) Massachusetts Medical Society. Reprinted with permission. https://www.nejm.org/author-center/permissions